213 related articles for article (PubMed ID: 38291366)
21. [TMEM64 is highly expressed in hepatocellular carcinoma and promotes tumor cell proliferation and invasion].
Cao D; Cai J; Li Y; Dong R; Wang Z; Zuo X
Nan Fang Yi Ke Da Xue Xue Bao; 2023 Aug; 43(8):1345-1355. PubMed ID: 37712271
[TBL] [Abstract][Full Text] [Related]
22. Comprehensive analysis of the correlation of the pan-cancer gene HAUS5 with prognosis and immune infiltration in liver cancer.
Zhang W; Yang C; Hu Y; Yi K; Xiao W; Xu X; Chen Z
Sci Rep; 2023 Feb; 13(1):2409. PubMed ID: 36765148
[TBL] [Abstract][Full Text] [Related]
23. Prognostic value of D-lactate dehydrogenase in patients with clear cell renal cell carcinoma.
Wang Y; Li G; Wan F; Dai B; Ye D
Oncol Lett; 2018 Jul; 16(1):866-874. PubMed ID: 29963157
[TBL] [Abstract][Full Text] [Related]
24. Overexpressed GNAZ predicts poor outcome and promotes G0/G1 cell cycle progression in hepatocellular carcinoma.
Tian F; Cai D
Gene; 2022 Jan; 807():145964. PubMed ID: 34530087
[TBL] [Abstract][Full Text] [Related]
25. Upregulated CANT1 is correlated with poor prognosis in hepatocellular carcinoma.
Liu T; Li ZZ; Sun L; Yang K; Chen JM; Han XY; Qi LM; Zhou XG; Wang P
BMC Cancer; 2023 Oct; 23(1):1007. PubMed ID: 37858061
[TBL] [Abstract][Full Text] [Related]
26. HSCs-derived COMP drives hepatocellular carcinoma progression by activating MEK/ERK and PI3K/AKT signaling pathways.
Li Q; Wang C; Wang Y; Sun L; Liu Z; Wang L; Song T; Yao Y; Liu Q; Tu K
J Exp Clin Cancer Res; 2018 Sep; 37(1):231. PubMed ID: 30231922
[TBL] [Abstract][Full Text] [Related]
27. Emodin inhibits invasion and migration of hepatocellular carcinoma cells via regulating autophagy-mediated degradation of snail and β-catenin.
Qin B; Zeng Z; Xu J; Shangwen J; Ye ZJ; Wang S; Wu Y; Peng G; Wang Q; Gu W; Tang Y
BMC Cancer; 2022 Jun; 22(1):671. PubMed ID: 35715752
[TBL] [Abstract][Full Text] [Related]
28. Lactate dehydrogenase D serves as a novel biomarker for prognosis and immune infiltration in lung adenocarcinoma.
Zhang Y; Zhang T; Zhao Y; Wu H; Zhen Q; Zhu S; Hou S
BMC Cancer; 2023 Aug; 23(1):759. PubMed ID: 37587457
[TBL] [Abstract][Full Text] [Related]
29. Alpha1-ACT Functions as a Tumour Suppressor in Hepatocellular Carcinoma by Inhibiting the PI3K/AKT/mTOR Signalling Pathway via Activation of PTEN.
Zhu H; Liu Q; Tang J; Xie Y; Xu X; Huang R; Zhang Y; Jin K; Sun B
Cell Physiol Biochem; 2017; 41(6):2289-2306. PubMed ID: 28456796
[TBL] [Abstract][Full Text] [Related]
30. CircCCNB1 silencing acting as a miR-106b-5p sponge inhibited GPM6A expression to promote HCC progression by enhancing DYNC1I1 expression and activating the AKT/ERK signaling pathway.
Liu YM; Cao Y; Zhao PS; Wu LY; Lu YM; Wang YL; Zhao JF; Liu XG
Int J Biol Sci; 2022; 18(2):637-651. PubMed ID: 35002514
[No Abstract] [Full Text] [Related]
31. [Pan-cancer analysis of the expression pattern of long non-coding RNA MIR22HG].
Wang H; Li W; Zhang D
Nan Fang Yi Ke Da Xue Xue Bao; 2022 Apr; 42(4):473-485. PubMed ID: 35527483
[TBL] [Abstract][Full Text] [Related]
32. Multi-omics analysis of the oncogenic value of copper Metabolism-Related protein COMMD2 in human cancers.
Tai P; Wang Z; Chen X; Chen A; Gong L; Cheng Y; Cao K
Cancer Med; 2023 May; 12(10):11941-11959. PubMed ID: 36205192
[TBL] [Abstract][Full Text] [Related]
33. A pan-cancer analysis of the oncogenic role of ribonucleotide reductase subunit M2 in human tumors.
Li Y; Fu W; Geng Z; Song Y; Yang X; He T; Wu J; Wang B
PeerJ; 2022; 10():e14432. PubMed ID: 36518297
[TBL] [Abstract][Full Text] [Related]
34. A potential immunotherapeutic and prognostic biomarker for multiple tumors including glioma: SHOX2.
Wu X; Chen H; You C; Peng Z
Hereditas; 2023 May; 160(1):21. PubMed ID: 37170390
[TBL] [Abstract][Full Text] [Related]
35. Lactate dehydrogenase B as a metabolism-related marker for immunotherapy in head and neck squamous cell carcinoma.
Xu X; Pan X; Fan Z; Xia J; Ren X
Cell Signal; 2024 May; 120():111200. PubMed ID: 38719019
[TBL] [Abstract][Full Text] [Related]
36. MYO18B promotes hepatocellular carcinoma progression by activating PI3K/AKT/mTOR signaling pathway.
Zhang Z; Zhu J; Huang Y; Li W; Cheng H
Diagn Pathol; 2018 Nov; 13(1):85. PubMed ID: 30390677
[TBL] [Abstract][Full Text] [Related]
37. The expression of chitinase 3-like 1: a novel prognostic predictor for hepatocellular carcinoma.
Pan JJ; Ge YS; Xu GL; Jia WD; Liu WF; Li JS; Liu WB
J Cancer Res Clin Oncol; 2013 Jun; 139(6):1043-54. PubMed ID: 23525579
[TBL] [Abstract][Full Text] [Related]
38. PRMT4 promotes hepatocellular carcinoma progression by activating AKT/mTOR signaling and indicates poor prognosis.
Du P; Luo K; Li G; Zhu J; Xiao Q; Li Y; Zhang X
Int J Med Sci; 2021; 18(15):3588-3598. PubMed ID: 34522186
[No Abstract] [Full Text] [Related]
39. CPNE1 is a potential prognostic biomarker, associated with immune infiltrates and promotes progression of hepatocellular carcinoma.
Su J; Huang Y; Wang Y; Li R; Deng W; Zhang H; Xiong H
Cancer Cell Int; 2022 Feb; 22(1):67. PubMed ID: 35139863
[TBL] [Abstract][Full Text] [Related]
40. Characterization of prognostic value and immunological roles of RAB22A in hepatocellular carcinoma.
Wen F; Meng F; Li X; Li Q; Liu J; Zhang R; Zhao Y; Zhang Y; Wang X; Ju S; Cui Y; Lu Z
Front Immunol; 2023; 14():1086342. PubMed ID: 36936971
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
